Compare CDNL & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDNL | SGP |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | N/A | 65 |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.9M | 643.9M |
| IPO Year | N/A | N/A |
| Metric | CDNL | SGP |
|---|---|---|
| Price | $52.07 | $19.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $38.00 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 459.0K | 50.1K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $50.30 | N/A |
| Revenue Next Year | $8.41 | N/A |
| P/E Ratio | $0.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.98 | $19.46 |
| 52 Week High | $63.18 | $30.56 |
| Indicator | CDNL | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 51.89 | 29.82 |
| Support Level | $46.60 | N/A |
| Resistance Level | $54.55 | $26.29 |
| Average True Range (ATR) | 4.86 | 1.59 |
| MACD | -0.62 | -0.38 |
| Stochastic Oscillator | 32.09 | 2.61 |
Cardinal Infrastructure Group Inc provides a comprehensive suite of infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. Its operations leverage a large highly skilled workforce and a fleet of specialized equipment to deliver wet utility installations (water, sewer, and stormwater systems), as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.